143 related articles for article (PubMed ID: 37792024)
1. Clozapine N-oxide, compound 21, and JHU37160 do not influence effortful reward-seeking behavior in mice.
Aomine Y; Oyama Y; Sakurai K; Macpherson T; Ozawa T; Hikida T
Psychopharmacology (Berl); 2024 Jan; 241(1):89-96. PubMed ID: 37792024
[TBL] [Abstract][Full Text] [Related]
2. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
Lawson KA; Ruiz CM; Mahler SV
Psychopharmacology (Berl); 2023 Oct; 240(10):2101-2110. PubMed ID: 37530882
[TBL] [Abstract][Full Text] [Related]
3. Effects of clozapine-N-oxide and compound 21 on sleep in laboratory mice.
Traut J; Mengual JP; Meijer EJ; McKillop LE; Alfonsa H; Hoerder-Suabedissen A; Song SH; Fehér KD; Riemann D; Molnar Z; Akerman CJ; Vyazovskiy VV; Krone LB
Elife; 2023 Mar; 12():. PubMed ID: 36892930
[TBL] [Abstract][Full Text] [Related]
4. Does chronic systemic injection of the DREADD agonists clozapine-N-oxide or Compound 21 change behavior relevant to locomotion, exploration, anxiety, and depression in male non-DREADD-expressing mice?
Tran FH; Spears SL; Ahn KJ; Eisch AJ; Yun S
Neurosci Lett; 2020 Nov; 739():135432. PubMed ID: 33080350
[TBL] [Abstract][Full Text] [Related]
5. A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition.
Lawson KA; Ruiz CM; Mahler SV
bioRxiv; 2023 Mar; ():. PubMed ID: 37034819
[TBL] [Abstract][Full Text] [Related]
6. The DREADD agonist clozapine N-oxide (CNO) is reverse-metabolized to clozapine and produces clozapine-like interoceptive stimulus effects in rats and mice.
Manvich DF; Webster KA; Foster SL; Farrell MS; Ritchie JC; Porter JH; Weinshenker D
Sci Rep; 2018 Mar; 8(1):3840. PubMed ID: 29497149
[TBL] [Abstract][Full Text] [Related]
7. Abnormalities in the composition of the gut microbiota in mice after repeated administration of DREADD ligands.
Guo W; Wan X; Ma L; Zhang J; Hashimoto K
Brain Res Bull; 2021 Aug; 173():66-73. PubMed ID: 34004259
[TBL] [Abstract][Full Text] [Related]
8. Validation of DREADD agonists and administration route in a murine model of sleep enhancement.
Ferrari LL; Ogbeide-Latario OE; Gompf HS; Anaclet C
J Neurosci Methods; 2022 Oct; 380():109679. PubMed ID: 35914577
[TBL] [Abstract][Full Text] [Related]
9. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine.
Gomez JL; Bonaventura J; Lesniak W; Mathews WB; Sysa-Shah P; Rodriguez LA; Ellis RJ; Richie CT; Harvey BK; Dannals RF; Pomper MG; Bonci A; Michaelides M
Science; 2017 Aug; 357(6350):503-507. PubMed ID: 28774929
[TBL] [Abstract][Full Text] [Related]
10. The first structure-activity relationship studies for designer receptors exclusively activated by designer drugs.
Chen X; Choo H; Huang XP; Yang X; Stone O; Roth BL; Jin J
ACS Chem Neurosci; 2015 Mar; 6(3):476-84. PubMed ID: 25587888
[TBL] [Abstract][Full Text] [Related]
11. Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments.
MacLaren DA; Browne RW; Shaw JK; Krishnan Radhakrishnan S; Khare P; España RA; Clark SD
eNeuro; 2016; 3(5):. PubMed ID: 27822508
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent reduction in cocaine-induced locomotion by Clozapine-N-Oxide in rats with a history of cocaine self-administration.
Padovan-Hernandez Y; Knackstedt LA
Neurosci Lett; 2018 May; 674():132-135. PubMed ID: 29571824
[TBL] [Abstract][Full Text] [Related]
13. High dose administration of DREADD agonist JHU37160 produces increases in anxiety-like behavior in male rats.
Van Savage J; Avegno EM
Behav Brain Res; 2023 Aug; 452():114553. PubMed ID: 37352979
[TBL] [Abstract][Full Text] [Related]
14. Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model.
Desloovere J; Boon P; Larsen LE; Goossens MG; Delbeke J; Carrette E; Wadman W; Vonck K; Raedt R
Neurotherapeutics; 2022 Jan; 19(1):342-351. PubMed ID: 34862591
[TBL] [Abstract][Full Text] [Related]
15. Behavioral Effect of Chemogenetic Inhibition Is Directly Related to Receptor Transduction Levels in Rhesus Monkeys.
Upright NA; Brookshire SW; Schnebelen W; Damatac CG; Hof PR; Browning PGF; Croxson PL; Rudebeck PH; Baxter MG
J Neurosci; 2018 Sep; 38(37):7969-7975. PubMed ID: 30082415
[TBL] [Abstract][Full Text] [Related]
16. G
Marciante AB; Farmer GE; Cunningham JT
J Neurophysiol; 2020 Aug; 124(2):591-609. PubMed ID: 32697679
[TBL] [Abstract][Full Text] [Related]
17. [A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals].
Nagai Y
Nihon Yakurigaku Zasshi; 2022; 157(4):233-237. PubMed ID: 35781451
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics.
Raper J; Morrison RD; Daniels JS; Howell L; Bachevalier J; Wichmann T; Galvan A
ACS Chem Neurosci; 2017 Jul; 8(7):1570-1576. PubMed ID: 28324647
[TBL] [Abstract][Full Text] [Related]
19. Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems.
Schalbetter SM; Mueller FS; Scarborough J; Richetto J; Weber-Stadlbauer U; Meyer U; Notter T
Lab Anim (NY); 2021 Mar; 50(3):69-75. PubMed ID: 33619409
[TBL] [Abstract][Full Text] [Related]
20. Gi-DREADD Expression in Peripheral Nerves Produces Ligand-Dependent Analgesia, as well as Ligand-Independent Functional Changes in Sensory Neurons.
Saloman JL; Scheff NN; Snyder LM; Ross SE; Davis BM; Gold MS
J Neurosci; 2016 Oct; 36(42):10769-10781. PubMed ID: 27798132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
